This approach allows for the classification of tumors into four clinically relevant subtypes: prostatic adenocarcinoma (AR + /NE-), NEPC (AR-/NE + ), amphicrine carcinoma (AR + /NE + ) and double negative CRPC (AR-/NE-)20,37. Here, AR is linked to prostate adenocarcinoma.